Compare RELL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | SKYE |
|---|---|---|
| Founded | 1947 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 9.0M |
| IPO Year | 2004 | 2013 |
| Metric | RELL | SKYE |
|---|---|---|
| Price | $17.51 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 93.8K | 81.8K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $228,564,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $9.37 | $0.26 |
| 52 Week High | $23.15 | $4.99 |
| Indicator | RELL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 50.51 |
| Support Level | $16.40 | $1.57 |
| Resistance Level | $17.94 | $2.28 |
| Average True Range (ATR) | 0.60 | 0.23 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 84.16 | 16.00 |
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.